Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

Articles published in
Ann Neurol
    June 2022
  1. MAGLIOZZI R, Fadda G, Brown RA, Bar-Or A, et al
    "Ependymal-in" gradient of thalamic damage in progressive multiple sclerosis.
    Ann Neurol. 2022 Jun 24. doi: 10.1002/ana.26448.
    >> Share

  2. RAHMANZADEH R, Galbusera R, Lu PJ, Bahn E, et al
    A new advanced MRI biomarker for remyelinated lesions in Multiple Sclerosis.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26441.
    >> Share

  3. OECHTERING J, Lincke T, Schaedelin S, Decard BF, et al
    Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
    Ann Neurol. 2022;91:814-820.
    >> Share

    May 2022
  4. ZEYDAN B, Rocca MA, Kantarci OH, Filippi M, et al
    Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS.
    Ann Neurol. 2022;91:734-735.
    >> Share

  5. GHIROTTO B, Oliveira DF, Cipelli M, Basso PJ, et al
    MS-Driven Metabolic Alterations Are Recapitulated in iPSC-Derived Astrocytes.
    Ann Neurol. 2022;91:652-669.
    >> Share

  6. DIEBOLD M, Galli E, Kopf A, Sanderson N, et al
    Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Ann Neurol. 2022;91:676-681.
    >> Share

    April 2022
  7. BOSE G, Healy BC, Lokhande HA, Sotiropoulos MG, et al
    Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26370.
    >> Share

    March 2022
  8. KISTER I, Patskovsky Y, Curtin R, Pei J, et al
    Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study.
    Ann Neurol. 2022 Mar 15. doi: 10.1002/ana.26346.
    >> Share

  9. LANGER-GOULD A, Cheng SC, Li BH, Smith JB, et al
    Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26352.
    >> Share

  10. BRILL L, Raposo C, Rechtman A, Zveik O, et al
    SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab.
    Ann Neurol. 2022 Mar 4. doi: 10.1002/ana.26343.
    >> Share

    February 2022
  11. DE MEO E, Filippi M, Trojano M, Comi G, et al
    Comparing natural history of early and late onset pediatric multiple sclerosis.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26322.
    >> Share

    January 2022
  12. MCKAY KA, Bedri SK, Manouchehrinia A, Stawiarz L, et al
    Reduction in cognitive processing speed surrounding multiple sclerosis relapse.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301.
    >> Share

    December 2021
  13. FLEISCHER V, Ciolac D, Gonzalez-Escamilla G, Grothe M, et al
    Subcortical volumes as early predictors of fatigue in multiple sclerosis.
    Ann Neurol. 2021 Dec 30. doi: 10.1002/ana.26290.
    >> Share

  14. BISCHOF A, Papinutto N, Keshavan A, Rajesh A, et al
    Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis.
    Ann Neurol. 2021 Dec 8. doi: 10.1002/ana.26281.
    >> Share

    November 2021
  15. QUENDT C, Ochs J, Hausser-Kinzel S, Hausler D, et al
    Proinflammatory CD20(+) T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.
    Ann Neurol. 2021;90:834-839.
    >> Share

    October 2021
  16. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    >> Share

    September 2021
  17. KOCH MW, Kaur S, Sage K, Kim J, et al
    Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26239.
    >> Share

    August 2021
  18. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    >> Share

  19. PAN S, Chan JR
    Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
    >> Share

  20. KOLB H, Absinta M, Beck ES, Ha SK, et al
    7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
    >> Share

    July 2021
  21. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
    MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
    >> Share

  22. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    >> Share

  23. HAUSER SL
    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
    >> Share

    May 2021
  24. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
    Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
    Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
    >> Share

  25. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    >> Share

    April 2021
  26. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    >> Share

  27. PETZOLD A
    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    >> Share

  28. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    >> Share

  29. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    >> Share

    March 2021
  30. VANDEBERGH M, Andlauer TFM, Zhou Y, Mallants K, et al
    Genetic variation in WNT9B increases relapse hazard in multiple sclerosis.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26061.
    >> Share

  31. NOURBAKHSH B, Cordano C, Asteggiano C, Ruprecht K, et al
    Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062.
    >> Share

    February 2021
  32. DE MEO E, Bonacchi R, Moiola L, Colombo B, et al
    Early predictors of 9-year disability in pediatric multiple sclerosis.
    Ann Neurol. 2021 Feb 17. doi: 10.1002/ana.26052.
    >> Share

    January 2021
  33. SORMANI MP, De Rossi N, Schiavetti I, Carmisciano L, et al
    Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.
    Ann Neurol. 2021 Jan 21. doi: 10.1002/ana.26028.
    >> Share

    November 2020
  34. THAM M, Frischer JM, Weigand SD, Fitz-Gibbon PD, et al
    Iron heterogeneity in early active multiple sclerosis lesions.
    Ann Neurol. 2020 Nov 27. doi: 10.1002/ana.25974.
    >> Share

  35. FADDA G, Banwell B, Waters P, Marrie RA, et al
    Silent new brain MRI lesions in children with MOG-antibody associated disease.
    Ann Neurol. 2020 Nov 19. doi: 10.1002/ana.25957.
    >> Share

    October 2020
  36. SOTIRCHOS ES, Calabresi PA, Saidha S
    Reply to "Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?"
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25936.
    >> Share

  37. CORDANO C, Yiu HH, Oertel FC, Gelfand JM, et al
    Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25933.
    >> Share

  38. COMI G, Bar-Or A, Lassmann H, Uccelli A, et al
    The role of B cells in Multiple Sclerosis and related disorders.
    Ann Neurol. 2020 Oct 9. doi: 10.1002/ana.25927.
    >> Share

    September 2020
  39. CIOTTI JR, Grebenciucova E, Moss BP, Newsome SD, et al
    Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25907.
    >> Share

    August 2020
  40. MAGGI P, Sati P, Nair G, Cortese ICM, et al
    PARAMAGNETIC RIM LESIONS ARE SPECIFIC TO MULTIPLE SCLEROSIS: AN INTERNATIONAL MULTICENTER 3T MRI STUDY.
    Ann Neurol. 2020 Aug 15. doi: 10.1002/ana.25877.
    >> Share

  41. PETZOLD A, Coric D, Balk LJ, Hamann S, et al
    Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis.
    Ann Neurol. 2020;88:309-319.
    >> Share

    July 2020
  42. KHOURY SJ
    Progressive Multiple Sclerosis.
    Ann Neurol. 2020 Jul 6. doi: 10.1002/ana.25802.
    >> Share

  43. KRYSKO KM, Graves JS, Rensel M, Weinstock-Guttman B, et al
    Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Ann Neurol. 2020;88:42-55.
    >> Share

    June 2020
  44. PETROVA N, Nutma E, Carassiti D, Newman J, et al
    Synaptic loss in the multiple sclerosis spinal cord.
    Ann Neurol. 2020 Jun 30. doi: 10.1002/ana.25835.
    >> Share

  45. FILIPPI M, Preziosa P, Langdon D, Lassmann H, et al
    Identifying Progression In Multiple Sclerosis: New Perspectives.
    Ann Neurol. 2020 Jun 7. doi: 10.1002/ana.25808.
    >> Share

  46. LEBRUN-FRENAY C, Kantarci O, Siva A, Sormani MP, et al
    Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
    Ann Neurol. 2020 Jun 4. doi: 10.1002/ana.25799.
    >> Share

    May 2020
  47. MAGLIOZZI R, Scalfari A, Pisani AI, Ziccardi S, et al
    The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
    Ann Neurol. 2020 May 17. doi: 10.1002/ana.25786.
    >> Share

  48. AMOR S, Baker D, Khoury SJ, Schmierer K, et al
    SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
    Ann Neurol. 2020 May 8. doi: 10.1002/ana.25770.
    >> Share

  49. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    >> Share

    April 2020
  50. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    >> Share

  51. DESAI RA, Davies AL, Del Rossi N, Tachrount M, et al
    Nimodipine reduces dysfunction and demyelination in models of multiple sclerosis.
    Ann Neurol. 2020 Apr 15. doi: 10.1002/ana.25749.
    >> Share

  52. MAHAJAN KR, Nakamura K, Cohen JA, Trapp BD, et al
    Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25743.
    >> Share

  53. COLE JH, Raffel J, Friede T, Eshaghi A, et al
    Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25746.
    >> Share

  54. SOTIRCHOS ES, Caldito NG, Filippatou A, Fitzgerald KC, et al
    Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy.
    Ann Neurol. 2020 Apr 13. doi: 10.1002/ana.25738.
    >> Share

    March 2020
  55. DE MOL CL, Jansen PR, Muetzel RL, Knol MJ, et al
    Polygenic multiple sclerosis risk and population-based childhood brain imaging.
    Ann Neurol. 2020 Mar 12. doi: 10.1002/ana.25717.
    >> Share

    February 2020
  56. OUELLETTE R, Mangeat G, Polyak I, Warntjes M, et al
    Validation of rapid magnetic resonance myelin imaging in multiple sclerosis.
    Ann Neurol. 2020 Feb 14. doi: 10.1002/ana.25705.
    >> Share

  57. ALPING P, Askling J, Burman J, Fink K, et al
    Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients.
    Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701.
    >> Share

    January 2020
  58. OLDONI E, Smets I, Mallants K, Vandebergh M, et al
    CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity.
    Ann Neurol. 2020 Jan 29. doi: 10.1002/ana.25691.
    >> Share

  59. DOBSON R, Jitlal M, Marshall CR, Noyce AJ, et al
    Ethnic and socioeconomic associations with multiple sclerosis risk.
    Ann Neurol. 2020 Jan 23. doi: 10.1002/ana.25688.
    >> Share

  60. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    >> Share

    November 2019
  61. CHUNG KK, Altmann D, Barkhof F, Miszkiel K, et al
    A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes.
    Ann Neurol. 2019 Nov 6. doi: 10.1002/ana.25637.
    >> Share

    August 2019
  62. LOONSTRA FC, Verberk IMW, Wijburg MT, Wattjes MP, et al
    Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Ann Neurol. 2019;86:322-324.
    >> Share

  63. DALLA COSTA G, Martinelli V, Furlan R, Comi G, et al
    Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Ann Neurol. 2019;86:324.
    >> Share

    May 2019
  64. NOLAN-KENNEY RC, Liu M, Akhand O, Calabresi PA, et al
    Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.
    Ann Neurol. 2019;85:618-629.
    >> Share

    February 2019
  65. DALLA COSTA G, Martinelli V, Moiola L, Sangalli F, et al
    Serum neurofilaments increase at PML onset in natalizumab-treated MS patients.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25437.
    >> Share

    January 2019
  66. CACCIAGUERRA L, Meani A, Mesaros S, Radaelli M, et al
    Brain and cord imaging features in neuromyelitis optica spectrum disorders.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25411.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016